Tolegen S. Kurmangaliyev

Tolegen S. Kurmangaliyev

Auto-generated profile, based on publicly available information

Tolegen S. Kurmangaliyev

«Center of Nuclear Medicine and Oncology», Semey, Republic of Kazakhstan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2022 in Russian Open Medical Journal
Verified
Journal Article
Closed access
OAOlga B. Andreyeva
Olga B. Andreyeva
TATasbolat Adylkhanov
Tasbolat Adylkhanov
Dilyara KaidarovaDilyara Kaidarova
Dilyara Kaidarova
IIIsa G. Isayev
Isa G. Isayev
TKTolegen S. Kurmangaliyev
Tolegen S. Kurmangaliyev
NGNatalya Glushkova
Natalya Glushkova
Rationale – The use of 3D image-guided brachytherapy (3D-IGBT) allows adequately optimizing the dose distribution to bring a target therapeutic dose to clinical target volume (CTV), thereby minimizing an impact on critical organs, while ensuring a decrease in the incidence and severity of radiation-caused complications. Use of 3D-IGBT also allows improving the quality of life in patients with cervical cancer. Objective – To conduct a preliminary analysis of the incidence of early and late radiation responses in 3D-IGBT of locally advanced cervical cancer (LACC). Materials and Methods – The objects of our study were female patients with stages IIB and IIIB of cervical squamous cell carcinoma, without confirmed metastases, preceding chemotherapy (CHT) and/or radiation therapy (RT), and surgical interventions in this localization, who underwent combined chemoradiotherapy during the study. Results – Statistically significant results were obtained when analyzing the incidence of late radiation responses. It is important to point out that when assessing early toxicity in the main group with 3D-IGBT, grade 3 responses were not diagnosed, while in the control group, they were observed in 4 (9.1%) women. For instance, the manifestation of grade 3 delayed radiation injuries in the rectum was diagnosed in 3 (6.8%) women in the control group, while in the main group, they were not detected. Grade 2 cystitis was observed in a smaller number of women in the group with 3D-IGBT, compared with the control group (9.1% vs. 13.6%, p<0.05). Grade 3 delayed radiation responses in the bladder were diagnosed in 4 (9.1%) women in the control group, whereas among the patients of the main group with 3D-IGBT, they were not recorded at all (p <0.05). Grade II reactions in the vaginal mucosa and cervix were diagnosed more often in the control group (16.7% vs. 13.6%, p<0.05). Conclusion – Hence, the method we have used to optimize the treatment of LACC by means of 3D planning in accordance with toxicity criteria exhibited a definite advantage, compared with RT with 2D planning. Based on the results of our research, we concluded that optimization of RT for LACC using 3D-IGBT created clinically favorable conditions for effective therapy: it reduced the risk of displacement of the applicators and decreased an impact on the patient via reducing the total radiation doses and incidence of severe early and late toxic effects, providing good outcomes of local control regardless of tumor size and clinical stage.

28 August 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
STS. Tanatarov
S. Tanatarov
BABayan Atantayeva
Bayan Atantayeva
TKT. Kurmangaliyev
T. Kurmangaliyev
BАB. Аpsalikov
B. Аpsalikov
Background. TP53 rs1042522 (Arg72Pro) is a functionally significant polymorphism that alters the apoptotic activity of the p53 protein and is potentially associated with cancer susceptibility. Its contribution to cancer risk in radiation-exposed populations remains insufficiently explored. This study aimed to analyze the frequency of this polymorphism in women with breast cancer residing near the former Semipalatinsk nuclear test site, considering both hereditary and environmental risk factors. Materials and methods. A case-control study was conducted involving 250 Kazakh women aged 40 to 79 years. Participants were categorized into groups based on cancer diagnosis, family history, and radiation exposure. Genotyping of the TP53 rs1042522 polymorphism was performed using real-time PCR. Statistical analysis included calculation of odds ratios (OR) with 95% confidence intervals (CIs), with Bonferroni correction applied where necessary. Results. The frequency of GC/CC genotypes was significantly higher among breast cancer patients with both a family history and documented radiation exposure (OR = 6.91; 95% CI: 1.89–25.21; p = 0.0020). A meaningful association was also observed in sporadic breast cancer cases – women with no known familial or radiation-related predisposition (OR = 4.30; 95% CI: 1.15–16.09; p = 0.0269). Genotype distribution in the control group was consistent with Hardy-Weinberg equilibrium, supporting the validity of sampling and genotyping procedures. Conclusion. The findings of this study suggest that the TP53 rs1042522 polymorphism may contribute to increased susceptibility to breast cancer in women exposed to ionizing radiation. These results highlight the importance of an integrated approach to cancer risk assessment that includes both genetic and environmental factors, and emphasize the need for further investigation of TP53 as a potential biomarker in vulnerable populations. Введение. TP53 rs1042522 (Arg72Pro) – функционально значимый полиморфизм, изменяющий апоптотическую активность белка p53 и потенциально ассоциированный с онкологической предрасположенностью. Влияние данного варианта на риск развития рака в условиях хронического радиационного воздействия остается недостаточно изученным. Настоящее исследование направлено на анализ частоты данного полиморфизма у женщин с раком молочной железы, проживающих вблизи бывшего Семипалатинского испытательного полигона, с учетом семейного анамнеза и истории радиационного воздействия. Материалы и методы. Исследование случай-контроль, включившее 250 женщин казахской национальности в возрасте от 40 до 79 лет. Участницы были разделены на группы в зависимости от диагноза, семейного анамнеза и радиационного воздействия. Генотипирование TP53 rs1042522 проводилось методом ПЦР в режиме реального времени. Статистический анализ включал расчет отношений шансов (OR) с 95% доверительными интервалами (CI) и поправку Бонферрони. Результаты. Частота генотипов GC/CC была достоверно выше среди женщин с раком молочной железы, имеющих как семейную отягощенность, так и историю радиационного воздействия (OR = 6,91; 95% CI: 1,89–25,21; p = 0,0020). Существенная ассоциация также наблюдалась в группе спорадических случаев – у пациенток без наследственной и радиационной предрасположенности (OR = 4,30; 95% CI: 1,15–16,09; p = 0,0269). В контрольной группе распределение генотипов соответствовало равновесию Харди-Вайнберга, что подтверждает корректность выборки и генотипирования. Выводы. Результаты исследования позволяют предположить участие полиморфизма TP53 rs1042522 в повышении чувствительности к раку молочной железы у женщин, подвергшихся радиационному воздействию. Это подчеркивает актуальность комплексного подхода к оценке онкогенного риска, включающего как генетические, так и экологические параметры, а также необходимость дальнейшего изучения TP53 как потенциального биомаркера. Кіріспе. TP53 rs1042522 (Arg72Pro) – p53 ақуызының апоптоздық белсенділігіне әсер ететін функционалды маңызды полиморфизм және онкологиялық бейімділікпен ықтимал байланысты генетикалық маркер. Бұл варианттың радиациялық әсерге ұшыраған адамдарда қатерлі ісік қаупіне әсері жеткілікті зерттелмеген. Осы...